Celularity, Inc. (NASDAQ:CELU) Shares Shorted: Short Interest Down 52.3% in September

by · The Markets Daily

Celularity, Inc. (NASDAQ:CELU – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 391,276 shares, a drop of 52.3% from the September 15th total of 821,020 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily trading volume, of 154,929 shares, the short-interest ratio is currently 2.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings raised Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Read Our Latest Analysis on Celularity

Celularity Trading Down 7.7%

NASDAQ CELU traded down $0.11 during trading hours on Wednesday, hitting $1.31. 47,821 shares of the company’s stock traded hands, compared to its average volume of 1,363,318. The business’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.03. The firm has a market capitalization of $42.51 million, a P/E ratio of -0.48 and a beta of 0.77. Celularity has a 52 week low of $0.56 and a 52 week high of $2.55.

Celularity (NASDAQ:CELU – Get Free Report) last announced its earnings results on Tuesday, September 29th. The company reported $0.02 EPS for the quarter. The business had revenue of $3.85 million for the quarter.

Institutional Investors Weigh In On Celularity

An institutional investor recently bought a new stake in Celularity stock. C V Starr & Co. Inc. acquired a new stake in shares of Celularity, Inc. (NASDAQ:CELU – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 764,069 shares of the company’s stock, valued at approximately $1,582,000. Celularity accounts for about 0.8% of C V Starr & Co. Inc.’s portfolio, making the stock its 4th largest holding. C V Starr & Co. Inc. owned about 2.64% of Celularity as of its most recent filing with the SEC. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Company Profile

(Get Free Report)

Celularity, Inc is a biotechnology company focused on developing cell therapies and biomaterial products derived from human placental tissue. The company’s platform is designed to use the placenta as a scalable source of allogeneic cells and biomaterials for applications in oncology, immune-mediated diseases, infectious diseases and tissue repair.

Celularity’s development pipeline has included placental-derived natural killer cell programs, including CYNK-001, which has been evaluated for potential use in hematologic cancers and other diseases.

Further Reading